News

Maviret is intended to be taken daily once for eight weeks. It is free from ribavirin and is a pan-genotypic treatment for patients not suffering from cirrhosis and

PFS is one of the three primary endpoints in the randomised, open-label, multi-centre, global trial, dubbed MYSTIC, which compared Imfinzi as a monotherapy or in combination with tremelimumab

The focus will be on a range of newly discovered RNA modulating enzyme targets. Evotec and STORM have been collaborating since 2016 in high-throughput screening and structural biology

In its letter to Eagle, the FDA has requested that the Company conduct an additional clinical trial for RYANODEX for Exertional Heat Stroke. “We are reviewing our options

The British pharma giant also said that it is weighing options for its Rare Diseases business which it is looking to divest in the near future following a

The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents β-lactam antibiotic resistance, but with the same safe and

Proceeds will be used to advance the company’s portfolio, including lead product candidate VNRX-5133 for multi-drug resistant (MDR) gram-negative infections. In connection with the financing, Versant Partner Carlo

The litigation related primarily to allegations that Celgene promoted Thalomid (thalidomide) for off-label uses before its 2006 FDA approval for newly diagnosed multiple myeloma. The Department of Justice,

The trial dubbed KEYNOTE-040 was held in patients who had previously undergone treatment for HNSCC and whose disease had recurred or is in a metastatic stage. While the